在血液恶性新生体患者中,社会经济地位和整体生存率
Lars Hernández Nielsen1, Daniel Tuyet Kristensen1,2, Lasse Hjort Jakobsen2,3,4
1Center for Clinical Data Science, Department of Clinical Medicine, Aalborg University and Research, Education and Innovation, Aalborg University Hospital, Aalborg, Denmark.
JAMA network open
|March 4, 2024
概括
对多发性骨髓瘤和扩散性大B细胞淋巴瘤等侵袭性血液癌症的存活率在社会经济群体中有所改善. 然而,急性髓性白血病的生存差异仍然存在,特别是在早期诊断年份.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 流行病学 流行病学
背景情况:
- 减少癌症存活率的社会经济差异是医疗保健的一个关键目标.
- 了解血液性恶性瘤的生存趋势对于有针对性的干预至关重要.
研究的目的:
- 检查社会经济地位 (SES) 如何影响多发性骨髓瘤 (MM),急性骨髓性白血病 (AML) 和扩散性大B细胞淋巴瘤 (DLBCL) 的生存时间.
主要方法:
- 在丹麦 (2005-2020年) 进行的一项全国性基于人口的队列研究分析了来自25-65岁的5677名患者的数据.
- 教育水平作为SES的代理.
- 使用卡普兰-梅尔和考克斯回归模型评估整体存活率 (OS),按诊断年份分层.
主要成果:
- 在研究期间,MM,AML和DLBCL的两年生存状况有所改善.
- 对于MM或DLBCL,没有发现与SES相关的显著生存差异.
- 低SES的AML患者的生存率较差,尽管近年来这一差距缩小了,主要是在诊断后的头两年内.
结论:
- 对于MM,AML和DLBCL,生存率总体上有所改善.
- 虽然MM和DLBCL的生存率在SES组之间是公平的,但AML的结果显示了与社会经济因素相关的持续差异,特别是在疾病过程的早期.
- 对导致这些差异的AML特异性因素进行进一步的研究是有必要的.
相关概念视频
Cancer Survival Analysis
345
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
345
Comparing the Survival Analysis of Two or More Groups
186
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
186
Kaplan-Meier Approach
137
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
137
Regulation of Hematopoietic Stem Cells
3.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K
Hematopoiesis
5.3K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
5.3K
Cancer Stem Cells and Tumor Maintenance
4.9K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.9K


